TSC2: filling the GAP in the mTOR signaling pathway

被引:336
作者
Li, Y
Corradetti, MN
Inoki, K
Guan, KL [1 ]
机构
[1] Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA
关键词
D O I
10.1016/j.tibs.2003.11.007
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The tumor-suppressor proteins TSC1 and TSC2 are associated with an autosomal dominant disorder known as tuberous sclerosis complex (TSC). TSC1 and TSC2 function as a heterodimer to inhibit cell growth and proliferation. Another protein, mTOR (mammalian target of rapamycin), is regarded as a central controller of cell growth in response to growth factors, cellular energy and nutrient levels. Recent breakthroughs in TSC research link the TSC1/2 heterodimer protein to the mTOR signaling network. It has recently been shown that TSC2 has GTPase-activating protein (GAP) activity towards the Ras family small GTPase Rheb (Ras homolog enriched in brain), and TSC1/2 antagonizes the mTOR signaling pathway via stimulation of GTP hydrolysis of Rheb. Thus, TSC1/2 and Rheb have pivotal roles in mediating growth factors, nutrient and energy sensing signals to mTOR-dependent targets. These discoveries lend new insight into TSC pathogenesis.
引用
收藏
页码:32 / 38
页数:7
相关论文
共 77 条
  • [1] Identification of TOR signaling complexes: more TORC for the cell growth engine
    Abraham, RT
    [J]. CELL, 2002, 111 (01) : 9 - 12
  • [2] Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration
    Astrinidis, A
    Cash, TP
    Hunter, DS
    Walker, CL
    Chernoff, J
    Henske, EP
    [J]. ONCOGENE, 2002, 21 (55) : 8470 - 8476
  • [3] The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination
    Benvenuto, G
    Li, SW
    Brown, SJ
    Braverman, R
    Vass, WC
    Cheadle, JP
    Halley, DJJ
    Sampson, JR
    Wienecke, R
    DeClue, JE
    [J]. ONCOGENE, 2000, 19 (54) : 6306 - 6316
  • [4] Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner
    Castro, AF
    Rebhun, JF
    Clark, GJ
    Quilliam, LA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (35) : 32493 - 32496
  • [5] Molecular genetic advances in tuberous sclerosis
    Cheadle, JP
    Reeve, MP
    Sampson, JR
    Kwiatkowski, DJ
    [J]. HUMAN GENETICS, 2000, 107 (02) : 97 - 114
  • [6] GEFs: structural basis for their activation of small GTP-binding proteins
    Cherfils, J
    Chardin, P
    [J]. TRENDS IN BIOCHEMICAL SCIENCES, 1999, 24 (08) : 306 - 311
  • [7] Clark GJ, 1997, J BIOL CHEM, V272, P10608
  • [8] Farnesyltransferase inhibitors: promises and realities
    Cox, AD
    Der, CJ
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2002, 2 (04) : 388 - 393
  • [9] RETRACTED: Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin (Retracted Article)
    Dan, HC
    Sun, M
    Yang, L
    Feldman, RI
    Sui, XM
    Ou, CC
    Nellist, M
    Yeung, RS
    Halley, DJJ
    Nicosia, SV
    Pledger, WJ
    Cheng, JQ
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (38) : 35364 - 35370
  • [10] GTPase activating proteins: critical regulators of intracellular signaling
    Donovan, S
    Shannon, KM
    Bollag, G
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2002, 1602 (01): : 23 - 45